FDA OKs Eravacycline for Complicated Intra-Abdominal Infections – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Officials with the US Food and Drug Administration (FDA) have approved eravacycline, (Xerava, Tetraphase Pharmaceuticals) for the treatment of complicated intra-abdominal infection (cIAI) in adults 18 years and older.
Eravacycline is a tetracycline-class antibacterial injection that has demonstrated potent activity against multidrug-resistant pathogens. In clinical trials, eravacycline was well tolerated, produced favorable results in curing patients with cIAIs, and demonstrated non-inferiority to ertapenem and meropenem.
The drug does not have a dose adjustment requirement when given to patients with renal impairment and it may be given to patients with penicillin allergies, according to a statement issued by Tetraphase.